



Shibrika Pansy, MS<sup>1</sup>, Carla Kmett Danielson, PhD<sup>2</sup>, Erin Bisca, MA<sup>2</sup>, Nathaniel Baker, MS<sup>2</sup>, Stephaine Amaya, PhD<sup>2</sup>, Taylor Wilson, MA<sup>2</sup>, Cristina Lopez, PhD<sup>2</sup> <sup>1</sup>Howard University College of Medicine, Washington, DC, <sup>2</sup>Department of Psychiatry and Behavorial Sciences, Medical University of South Carolina, Charleston, SC

### BACKGROUND

- People with HIV (PWH) report higher levels of trauma than the general population, with rates from 40 to 90% (1,2).
- Higher rates of traumatic exposure correspond with higher rates of Post-traumatic Stress Disorder (PTSD) in this population, with rates of PTSD in PWH estimated to be between 30 and 74% (3).
- Up to 64% of PWH endorse PTSD symptoms directly related to their HIV diagnosis (3).
- Our team recently enhanced Cognitive Processing Therapy (CPT), an evidence-based treatment for PTSD, with Lifesteps (L), an HIV medication adherence intervention, to create CPT-L to address PTSD and HIV outcomes.
- The purpose of the current study is to report on preliminary HIV stigma and PTSD findings among a small sample participating in a pilot randomized controlled trial comparing CPT-L to Standard of Care (SOC).

## METHODS

- PWH (N=41; Mean age=44.8; SD=12.3) who had experienced at least one traumatic event with current PTSD symptoms were recruited from local Ryan White HIV care clinics.
- Participants were randomized at baseline to received CPT-L or SOC and completed validated assessments of PTSD (Clinician Administered PTSD Scale for DSM-V/CAPS) and HIV stigma at baseline and at 6-week postbaseline.

### Demographics

	Overall	CPT-L	LifeSteps
Age	44.8 (12.3)	49.1 (11.8)	40.8 (11.6)
Race			
Black	61.0% (25)	55.0% (11)	66.7% (14)
White	29.3% (12)	40.0% (8)	19.1% (4)
MTO/Other	9.8% (4)	5.0% (1)	14.3% (3)
SABV			
Male	63.4% (26)	65.0% (13)	61.9% (13)
Female	36.6% (15)	35.0% (7)	38.1% (8)

# Does Enhanced Cognitive Processing Therapy with Lifesteps Reduce HIV Stigma and PTSD Symptoms Among People with HIV?: Preliminary Results from a Pilot Randomized Controlled Trial

# METHODS

- We assessed changes in clinician and participant-rated PTSD severity between CPT-L and SOC during study treatment and explored race and biological sex as possible treatment moderators. Data are presented as means and associated standard errors at study baseline, end of treatment (week 6) and the change between.
- Within group changes and between group differences are presented as Cohen's d values.
- Although not specifically powered to detect statistical effects, univariable and multivariable regression models were utilized to determine significance of main effects and interactions of interest.


### Retention to week 6 PTSD scores from baseline.


	Baseline	Week 6	Retention %
Overall	41	28	68.3%
CPT-L	20	11	55.0%
Lifesteps	21	17	80.9%

### Following 6 weeks of study treatment, participants in the CPT-L group showed significant decreases in clinician rated PTSD severity (CAPS: CPT-L $\Delta$ =-17.7, SE=2.4 vs. SOC $\Delta$ =-6.2, SE=4.0; Cohen's d=1.0).

- Statistical models noted that evidence of differential effect of sex on treatment outcomes by treatment group were present, indicating that males receiving CPT-L had a significantly greater decrease in CAPS as compared to females receiving CPT-L (Males  $\Delta$ =-25.3, SE=4.2 vs. Females  $\Delta$ =-8.6, SE=4.7; d=1.61) while the sex difference in the SOC group was null (d=0.06).
- Participants identifying as Black had significantly greater decreases in CAPS scores during treatment as compared to all other races (Black  $\Delta$ =-13.8, SE=2.8 vs. All Others  $\Delta$ =-6.0, SE=3.9; d=0.65), though this did not vary between treatment groups.
- Changes in HIV stigma total score from baseline to week 6 reached a Cohen's d of .97 within the CPT-L group but the between group difference was not significant ( $\Delta$ =6.22, SE=5.55, Cohen's d=0.43, p=.273).

## RESULTS







**Figure 2.** HIV Stigma by Treatment Condition from Baseline to 6-Weeks Post-Baseline



# CONCLUSIONS

The results of this preliminary study suggest CPT-L can be used as a tool to reduce PTSD and HIV stigma in PWH, particularly among males and Black people. Findings support the national U=U campaign (Undetectable + Untransmittable) to address HIV stigma and empower PWH.

The impact of race and gender on CPT-L treatment should be further studied in a larger sample of people to ensure accurate results.

Future research directions should explore ways in which physicians who work with PWH can best integrate CPT-L into their practices to promote a larger scale impact in the reduction of PTSD and HIV stigma, and, ultimately, improvement in HIV health outcomes.

## REFERENCES

1. C. Brezing, M. Ferrara, O. Freudenreich, The syndemic illness of HIV and trauma: implications for a trauma-informed model of care, Psychosomatics 56 (2) (2015)107–118, https://doi.org/10.1016/j.psym.2014.10.006.

2. 2. J. Leserman, K. Whetten, K. Lowe, D. Stangl, M.S. Swartz, N.M. Thielman, How trauma, recent stressful events, and PTSD affect functional health status and health utilization in HIV-infected patients in the south, Psychosom. Med. 67 (3) (2005) 500–507, https://doi.org/10.1097/01.psy.0000160459.781 <u>82.d9</u>.

3. S.A. Safren, B.S. Gershuny, E. Hendriksen, Symptoms of posttraumatic stress and death anxiety in persons with HIV and medication adherence difficulties, AIDS Patient Care STDS 17 (12) (2003) 657–664, https://doi.org/10.1089/108729103771928717.

## ACKNOWLEDGEMENTS

This work was supported by NIMH (R34MH125706) and the DART program. I would like to thank all members of the Invictus Lab, especially Dr. Danielson and Dr. Lopez for their guidance and mentorship throughout the duration of the DART program.